Guidance
Update information
November 2024: We have reviewed the evidence and made new recommendations on diagnosis, treatment and monitoring for people with asthma. These recommendations are marked [BTS/NICE/SIGN 2024].
We have also made some changes without an evidence review. These are marked [NICE 2020, amended BTS/NICE/SIGN 2024], [BTS/SIGN 2019, amended BTS/NICE/SIGN 2024], [NICE 2017, amended BTS/NICE/SIGN 2024] or [NICE 2017, BTS/SIGN 2019, amended BTS/NICE/SIGN 2024]. We have updated the wording in line with current best practice.
We have also made some minor changes – for example for clarity or where recommendations have been amalgamated. These recommendations are marked [NICE 2017], [NICE 2017, amended NICE 2021] or [BTS/SIGN 2019].
March 2021: In recommendations 1.14.1 and 1.14.3, NICE clarified that approaches to minimising indoor air pollution and reducing exposure to outdoor air pollution should be included in a personalised action plan because pollution can trigger and exacerbate asthma.
February 2020: NICE reviewed the evidence on increasing the dose of inhaled corticosteroids within a self-management programme in children and young people with asthma and removed a recommendation. A new recommendation on self-management in children and young people was made. This recommendation is marked [2020, amended BTS/NICE/SIGN 2024].
BTS ISBN: 978-1-917619-01-1
NICE ISBN: 978-1-4731-6612-7
SIGN ISBN: 978-1-909103-92-4